| 44.97 -0.19 (-0.42%) | 09-09 11:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 54.67  |
1-year : | 56.83 |
| Resists | First : | 46.81 |
Second : | 48.65 |
| Pivot price | 46.36 |
|||
| Supports | First : | 43.82 |
Second : | 36.45 |
| MAs | MA(5) : | 46.21 |
MA(20) : | 46.16 |
| MA(100) : | 45.37 |
MA(250) : | 46.36 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 20.1 |
D(3) : | 40.2 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 61.1 | Low : | 34.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed above bottom band by 15.7%. Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.93 - 46.24 | 46.24 - 46.49 |
| Low: | 44.55 - 44.85 | 44.85 - 45.1 |
| Close: | 44.72 - 45.21 | 45.21 - 45.61 |
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Wed, 09 Sep 2026
Novo Nordisk stock dips as DKK 15 billion buyback advances - AD HOC NEWS
Wed, 09 Sep 2026
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Tue, 08 Sep 2026
Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement - TradingKey
Tue, 08 Sep 2026
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO - ACCESS Newswire
Tue, 08 Sep 2026
Novo Nordisk (NVO) Draws Fresh Valuation Focus, Is It Still 55% Below Fair Value? - simplywall.st
Tue, 08 Sep 2026
Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted (Rating Downgrade) (NVO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,350 (M) |
| Shares Float | 3,170 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 33,830 (K) |
| Shares Short P.Month | 31,090 (K) |
| EPS | 4.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.73 |
| Profit Margin | 35.3 % |
| Operating Margin | 42.5 % |
| Return on Assets (ttm) | 18.7 % |
| Return on Equity (ttm) | 59.8 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 80.62 |
| Sales Per Share | 98.33 |
| EBITDA (p.s.) | 51.84 |
| Qtrly Earnings Growth | -20.7 % |
| Operating Cash Flow | 131,880 (M) |
| Levered Free Cash Flow | 37,670 (M) |
| PE Ratio | 11.06 |
| PEG Ratio | 3.3 |
| Price to Book value | 5.81 |
| Price to Sales | 0.45 |
| Price to Cash Flow | 1.14 |
| Dividend | 0.57 |
| Forward Dividend | 0 |
| Dividend Yield | 1.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|